Abstract
The EMPA-REG OUTCOME trial recently demonstrated in persons with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD) the efficacy of empagliflozin in reducing CVD events, as well as heart failure hospitalizations, cardiac and total mortality. The potential impact of EMPA-REG
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.